Palisade Bio, Inc. (PALI) Reports In-Line Q3 EPS

Palisade Bio, Inc. (NASDAQ: PALI) reported Q3 EPS of ($0.08), in-line with the analyst estimate of ($0.08). Revenue for the quarter came in at $0 versus the consensus estimate of $0 .

For earnings history and earnings-related data on Palisade Bio, Inc. (PALI) click here.

You May Also Be Interested In

• Citi cuts Micron stock target, sees memory chip prices peaking in 2Q27
• Evommune, Inc. (EVMN) Misses Q2 EPS by 20c
• bioAffinity (BIAF) Tops Q2 EPS by 146c